Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

Helmut H. Albrecht, Peter Vytautas Dicpinigaitis, Eric P. Guenin

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200-400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediate-release formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin's effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.

Original languageEnglish (US)
Article number31
JournalMultidisciplinary Respiratory Medicine
Volume12
Issue number1
DOIs
StatePublished - Dec 11 2017

Fingerprint

Guaifenesin
Chronic Bronchitis
Respiratory Tract Infections
Mucus
Cough
Expectorants
Common Cold
Clinical Pharmacology
Therapeutic Uses
Tablets
Thorax
Pediatrics
Safety

Keywords

  • Chronic bronchitis
  • Cough
  • Expectorant
  • Extended-release (ER) formulation
  • Guaifenesin
  • Mucoactive agents
  • Mucociliary clearance; over-the-counter (OTC)
  • Mucus
  • Respiratory tract infections

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. / Albrecht, Helmut H.; Dicpinigaitis, Peter Vytautas; Guenin, Eric P.

In: Multidisciplinary Respiratory Medicine, Vol. 12, No. 1, 31, 11.12.2017.

Research output: Contribution to journalReview article

@article{8d31425f6bae4d13b0ceb48ccb53ba25,
title = "Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections",
abstract = "Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200-400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediate-release formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin's effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.",
keywords = "Chronic bronchitis, Cough, Expectorant, Extended-release (ER) formulation, Guaifenesin, Mucoactive agents, Mucociliary clearance; over-the-counter (OTC), Mucus, Respiratory tract infections",
author = "Albrecht, {Helmut H.} and Dicpinigaitis, {Peter Vytautas} and Guenin, {Eric P.}",
year = "2017",
month = "12",
day = "11",
doi = "10.1186/s40248-017-0113-4",
language = "English (US)",
volume = "12",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "Novamedia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

AU - Albrecht, Helmut H.

AU - Dicpinigaitis, Peter Vytautas

AU - Guenin, Eric P.

PY - 2017/12/11

Y1 - 2017/12/11

N2 - Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200-400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediate-release formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin's effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.

AB - Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200-400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediate-release formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin's effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.

KW - Chronic bronchitis

KW - Cough

KW - Expectorant

KW - Extended-release (ER) formulation

KW - Guaifenesin

KW - Mucoactive agents

KW - Mucociliary clearance; over-the-counter (OTC)

KW - Mucus

KW - Respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=85037687353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037687353&partnerID=8YFLogxK

U2 - 10.1186/s40248-017-0113-4

DO - 10.1186/s40248-017-0113-4

M3 - Review article

AN - SCOPUS:85037687353

VL - 12

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - 1

M1 - 31

ER -